Nanopore sequencing offers comparable accuracy to short-read NGS for IGH clonotyping in CLL, with advantages in cost and laboratory footprint. The study confirms reliable somatic hypermutation status ...
Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback